Compare · ELV vs YDES
ELV vs YDES
Side-by-side comparison of Elevance Health Inc. (ELV) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $85.33B, about 530.7x YDES ($160.8M).
- Over the past year, ELV is up 37.9% and YDES is down 82.8% - ELV leads by 120.7 points.
- ELV has been more active in the news (6 items in the past 4 weeks vs 3 for YDES).
- ELV has more recent analyst coverage (23 ratings vs 0 for YDES).
PerformanceELV+20.59%YDES-82.78%
2025-09-02+0.00%2026-07-22
- Company
- Elevance Health Inc.
- YD Bio Limited
- Price
- $388.39-1.30%
- $2.30-4.56%
- Market cap
- $85.33B
- $160.8M
- 1M return
- -1.61%
- -9.09%
- 1Y return
- +37.89%
- -82.78%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 3
- Recent ratings
- 23
- 0
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.
Latest YDES
- YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
- Director Lu Shao-Ta converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- Director Chang Kochi converted options into 5,749 units of Ordinary Shares, increasing direct ownership by 276% to 7,830 units (SEC Form 4)
- SEC Form EFFECT filed by YD Bio Limited
- SEC Form POS AM filed by YD Bio Limited
- YD Bio Limited Reports Full Year 2025 Financial Results
- SEC Form 20-F filed by YD Bio Limited
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi